Ryan G Kruger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10689969/publications.pdf

Version: 2024-02-01

46 papers	7,344 citations	109321 35 h-index	214800 47 g-index
47 all docs	47 docs citations	47 times ranked	11314 citing authors

#	Article	IF	Citations
1	EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 2012, 492, 108-112.	27.8	1,558
2	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell, 2013, 23, 677-692.	16.8	706
3	The promise and peril of chemical probes. Nature Chemical Biology, 2015, 11, 536-541.	8.0	698
4	Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2989-2994.	7.1	445
5	A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell, 2015, 28, 57-69.	16.8	414
6	Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Medicinal Chemistry Letters, 2012, 3, 1091-1096.	2.8	332
7	SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature, 2014, 510, 283-287.	27.8	331
8	Assembly of the SIR Complex and Its Regulation by O -Acetyl-ADP-Ribose, a Product of NAD-Dependent Histone Deacetylation. Cell, 2005, 121, 515-527.	28.9	242
9	Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell, 2019, 36, 100-114.e25.	16.8	196
10	Vinyl Sulfones:Â Inhibitors of SrtA, a Transpeptidase Required for Cell Wall Protein Anchoring and Virulence inStaphylococcus aureus. Journal of the American Chemical Society, 2004, 126, 3404-3405.	13.7	184
11	Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics, 2012, 7, 340-343.	2.7	158
12	Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Scientific Reports, 2018, 8, 9711.	3.3	128
13	Analysis of the Substrate Specificity of the Staphylococcus aureus Sortase Transpeptidase SrtA. Biochemistry, 2004, 43, 1541-1551.	2.5	126
14	Staphylococcus aureusSortase Transpeptidase SrtA:Â Insight into the Kinetic Mechanism and Evidence for a Reverse Protonation Catalytic Mechanismâ€. Biochemistry, 2005, 44, 11188-11200.	2.5	126
15	Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nature Communications, 2019, 10, 2723.	12.8	126
16	Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers, 2002, 66, 261-284.	2.4	104
17	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1002-1017.	13.2	99
18	LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPÎ±-dependent enhancers in AML. Blood, 2018, 131, 1730-1742.	1.4	92

#	Article	IF	Citations
19	Development of a high-performance liquid chromatography assay and revision of kinetic parameters for the Staphylococcus aureus sortase transpeptidase SrtA. Analytical Biochemistry, 2004, 326, 42-48.	2.4	91
20	Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Scientific Reports, 2017, 7, 17993.	3.3	85
21	Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: Minimal structural requirements for intermolecular complexation and fibril formation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7384-7389.	7.1	78
22	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nature Immunology, 2019, 20, 86-96.	14.5	71
23	A Systematic Investigation of the Synthetic Utility of Glycopeptide Glycosyltransferases. Journal of the American Chemical Society, 2005, 127, 10747-10752.	13.7	70
24	Functional Analysis of the Lipoglycodepsipeptide Antibiotic Ramoplanin. Chemistry and Biology, 2002, 9, 897-906.	6.0	56
25	Tailoring of Glycopeptide Scaffolds by the Acyltransferases from the Teicoplanin and A-40,926 Biosynthetic Operons. Chemistry and Biology, 2005, 12, 131-140.	6.0	55
26	Long Residence Time Inhibition of EZH2 in Activated Polycomb Repressive Complex 2. ACS Chemical Biology, 2014, 9, 622-629.	3.4	55
27	Development and Validation of Reagents and Assays for EZH2 Peptide and Nucleosome High-Throughput Screens. Journal of Biomolecular Screening, 2012, 17, 1279-1292.	2.6	54
28	Targeting Histone Methylation in Cancer. Cancer Journal (Sudbury, Mass), 2017, 23, 292-301.	2.0	54
29	Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Structure, 2016, 24, 774-781.	3.3	53
30	Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. Journal of Thoracic Oncology, 2019, 14, 1828-1838.	1.1	50
31	Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes. Haematologica, 2019, 104, 1156-1167.	3.5	50
32	CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell, 2018, 33, 1111-1127.e5.	16.8	48
33	Kinetic Analysis of Teicoplanin Glycosyltransferases and Acyltransferase Reveal Ordered Tailoring of Aglycone Scaffold to Reconstitute Mature Teicoplanin. Journal of the American Chemical Society, 2007, 129, 10082-10083.	13.7	47
34	A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation. Molecular Cancer Therapeutics, 2014, 13, 3062-3073.	4.1	44
35	Inhibition of the Staphylococcus aureus sortase transpeptidase SrtA by phosphinic peptidomimetics. Bioorganic and Medicinal Chemistry, 2004, 12, 3723-3729.	3.0	41
36	<i>In vitro</i> and <i>in vivo</i> induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor. Haematologica, 2021, 106, 1979-1987.	3.5	41

#	Article	IF	Citations
37	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer Discovery, 2019, 9, 872-889.	9.4	36
38	MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers. Oncogenesis, 2018, 7, 35.	4.9	28
39	Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia. Blood, 2013, 122, 3964-3964.	1.4	25
40	Synthesis of P1-Citronellyl-P2-Î±-d-pyranosyl pyrophosphates as potential substrates for the E. coli undecaprenyl-pyrophosphoryl-N-acetylglucoseaminyl transferase MurG. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 3107-3110.	2.2	24
41	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1002-1017.	13.2	23
42	Antitumor activity of LSD1 inhibitors in lung cancer. Molecular and Cellular Oncology, 2016, 3, e1117700.	0.7	22
43	Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10772-10805.	6.4	17
44	Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cellâ€“Mediated Antitumor Immune Responses. Cancer Immunology Research, 2022, 10, 420-436.	3.4	17
45	Glycosylation of glycopeptides: a comparison of chemoenzymatic and chemical methods. Tetrahedron: Asymmetry, 2005, 16, 599-603.	1.8	13
46	Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, asÂmono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia and Lymphoma, 2022, 63, 463-467.	1.3	13